Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Chief Commercial Officer | July 05, 2023 | July 06, 2023 |
| Kura Oncology, Inc.KURA · Entity 4871 | Chief Commercial Officer | August 21, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date July 05, 2023 · Filed July 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,146 |
Reported balance
After 2023-07-05 transaction · row 1
1 source rowRow 1 · 2023-07-05 · Sale · Disposed 3,854 · Balance 41,146 F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 11,250 shares of Common Stock underlying RSUs granted to the Reporting Person on June 27, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2: Represents the weighted average sale price of the shares sold from $4.82 to $4.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 11,250 shares of Common Stock underlying RSUs granted to the Reporting Person on June 27, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.
F2: Represents the weighted average sale price of the shares sold from $4.82 to $4.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth this footnote.
Kura Oncology, Inc.
Report date August 21, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 169,269 |
Reported balance
After 2026-08-21 transaction · row 1
1 source rowRow 1 · 2026-08-21 · Sale · Disposed 4,345 · Balance 169,269 F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. F2: This transaction was executed in multiple trades at prices ranging from $11.78 to $12.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $11.78 to $12.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 24, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,345 | $11.89 | $51,663.35 |
DisclosureSEC source: 0001193125-26-363810 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,269 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.78 to $12.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 10,000 | $11.00 | $110,000.00 |
DisclosureSEC source: 0001193125-26-236838 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,614 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 339 | $9.21 | $3,122.19 |
DisclosureSEC source: 0001193125-26-232547 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,614 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. F2 · shares: 678 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,572 | $8.46 | $13,300.22 |
DisclosureSEC source: 0001193125-26-025305 · ownership.xml · nonDerivative · entry 2 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,275 F2 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,842 | $8.46 | $40,966.23 |
DisclosureSEC source: 0001193125-26-025305 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,847 F1 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 100,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004564 · ownership.xml · derivative · entry 2 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004564 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,689 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 8,887 | $11.18 | $99,329.11 |
DisclosureSEC source: 0001193125-25-283564 · ownership.xml · nonDerivative · entry 2 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,689 F2 · kind: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 11/13/25. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 48,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-283564 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,576 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest 50% immediately and 50% on 11/13/26. Read SEC document |
| September 29, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 8,891 | $8.94 | $79,505.10 |
DisclosureSEC source: 0001193125-25-223667 · ownership.xml · nonDerivative · entry 2 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,676 F1 · kind: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 9/27/25. Read SEC document |
| September 27, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 48,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-223667 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,567 Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,583 | $7.87 | $12,461.22 |
DisclosureSEC source: 0000950170-25-010116 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,667 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:07 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 92,500 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0000950170-25-002056 · ownership.xml · derivative · entry 2 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2035-01-01 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:07 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 46,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002056 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,250 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/26, 1/26/27, 1/26/28 and 1/26/29. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 30,000 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0000950170-24-001849 · ownership.xml · derivative · entry 2 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001849 · ownership.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 20:09 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 200,000 | $0.00 Strike: $11.72 | $0.00 |
DisclosureSEC source: 0001209191-23-046002 · doc4.xml · derivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-08-13 F1 · derivative.exercise_date: 1/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 21:19 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 3,854 | $4.87 | $18,768.98 |
DisclosureSEC source: 0001209191-23-041611 · doc4.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,146 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 11,250 shares of Common Stock underlying RSUs granted to the Reporting Person on June 27, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold from $4.82 to $4.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth this footnote. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:16 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0001209191-23-007507 · doc4.xml · derivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2033-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2023, such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $26.25 | $0.00 |
DisclosureSEC source: 0001209191-22-039819 · doc4.xml · derivative · entry 2 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-06-27 F2 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on June 27, 2023 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039819 · doc4.xml · nonDerivative · entry 1 Powl Brian T. · CIK 0001934232 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · kind: Exempt grant of restricted stock units pursuant to the Issuer's Amended and Restated Inducement Equity Plan. 25% of the award will vest on July 1, 2023, and 25% of the remainder shall vest on July 1, 2024, July 1, 2025, and July 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.